APVO Aptevo Therapeutics Inc.
Company Updates ·
Ten patients with newly diagnosed AML advanced to transplant after treatment with mipletamig, venetoclax and azacitidine, according to Aptevo's October 26, 2026 release.
Aptevo will present its CD40-directed multispecific portfolio at the Society for Immunotherapy of Cancer annual meeting in Phoenix, November 4 to 8, 2026.
Aptevo is optimizing several trispecific candidates for scalable manufacturing and expects IND-enabling studies for its lead candidate, APVO451, in the first half of 2027.
Thirteen of 14 evaluable TP53-mutated frontline AML patients treated with mipletamig, venetoclax and azacitidine had clinical benefit, according to Aptevo's September 3, 2026 release.
Aptevo Therapeutics (Nasdaq: APVO) closed deals that cut warrant exercise prices to $4.03 per share and sold shares or pre-funded warrants in a private placement. Roth Capital Partners was placement agent.
Aptevo filed a patent application covering a Nectin-4 x PD-L1 dual-targeting backbone that it says could support radiopharmaceuticals, T-cell engagers and other immune-based approaches.
Aptevo was awarded a $1.5 million non-dilutive research grant from the Andy Hill CARE Fund to support IND-enabling work for APVO451, its nectin-4-targeted trispecific candidate.
Aptevo and Niowave agreed to a 50/50 collaboration to develop up to three radiopharmaceutical oncology programs, with Niowave making an at-the-market equity investment at closing.
Aptevo says its RAINIER trial of mipletamig remains on track for Phase 2 dose selection by year end, and that a $60 million standby equity purchase agreement extends its access to capital.
Aptevo says mipletamig data from 31 evaluable frontline AML patients show continued activity, and that the RAINIER trial has entered its final dose-optimization stage.
Aptevo says about $15.9 million of gross equity raised in the June quarter puts it back above Nasdaq's $2.5 million stockholders' equity minimum. The figure is the company's own belief, and it was still awaiting formal confirmation from Nasdaq.
Aptevo filed to sell up to 1,709,401 shares with five common warrants each and signed a $25.0 million equity line with Yorkville. Its auditor's report carries a going concern paragraph, and cash was $2,139 thousand at March 31, 2025.
Aptevo reported a stockholders' deficit of $1,473,000 against a $2,500,000 minimum. It also filed an at-the-market prospectus supplement for up to $3,015,515 of stock, and it set a 1-for-20 reverse stock split for May 23, 2025.
Aptevo Therapeutics Inc. is a clinical-stage, research and development biotechnology company developing novel immunotherapy candidates for different forms of cancer. Its two platform technologies, ADAPTIR and ADAPTIR-FLEX, are used to design monospecific and multi-specific antibody candidates that engage immune cells against tumors, and the company says it wholly owns both platforms. It has two clinical candidates and six preclinical candidates. The lead blood cancer candidate, mipletamig, is a CD123xCD3 T cell engager in the RAINIER trial, a Phase 1b/2 program initiated in August 2024 in frontline acute myelogenous leukemia in combination with venetoclax and azacitidine. The lead solid tumor candidate, ALG.APV-527, targets 4-1BB and 5T4 and was developed in partnership with Alligator Bioscience AB. In its dose escalation trial, 58% of nineteen patients achieved a best response of stable disease. The company says it is being evaluated for multiple solid tumor types, potentially including breast, cervical, non-small-cell lung, prostate, renal, gastric, colorectal and bladder cancers.
| Product or program | What it is | Stage |
|---|---|---|
| Mipletamig | CD123xCD3 T cell engager for frontline acute myelogenous leukemia | Phase 1b/2 RAINIER trial initiated August 2024 |
| ALG.APV-527 | Antibody targeting 4-1BB and 5T4 for multiple solid tumor types | clinical candidate; dose escalation trial reported |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $14.5 million | $14.4 million |
| Net income (loss) | -$26.0 million | -$24.1 million |
| Cash from operations | -$25.6 million | -$23.8 million |
| Cash and equivalents | $21.6 million | $8.7 million |
Our latest story on this, dated May 22, 2025: "Aptevo Therapeutics gets Nasdaq stockholders' equity notice, sets 1-for-20 reverse stock split". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jun 16, 2025: "Aptevo files stock and warrant offering, signs $25.0 million Yorkville equity line". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 13, 2026: "Aptevo Therapeutics closes warrant inducement and private placement for about $4.5 million". The story links the filing or release it is based on. Read the story.
Aptevo Therapeutics Inc. trades under the ticker APVO on NASDAQ.
Aptevo Therapeutics Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Aptevo Therapeutics Inc. is 1671584. Its filings are on SEC EDGAR.
1,801,970 shares as of 2026-08-14, per the cover page of its 10-Q filed 2026-08-14.
Our directory records Aptevo Therapeutics Inc. under United States.
Our directory classifies Aptevo Therapeutics Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Aptevo Therapeutics Inc. is US03835L7029.
aibio.space lists Aptevo Therapeutics Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Aptevo Therapeutics Inc. is a clinical-stage, research and development biotechnology company developing novel immunotherapy candidates for different forms of cancer. Its two platform technologies, ADAPTIR and ADAPTIR-FLEX, are used to design monospecific and multi-specific antibody candidates that engage immune cells against tumors, and the company says it wholly owns both platforms.
Mipletamig: CD123xCD3 T cell engager for frontline acute myelogenous leukemia Stage: Phase 1b/2 RAINIER trial initiated August 2024.
ALG.APV-527: Antibody targeting 4-1BB and 5T4 for multiple solid tumor types Stage: clinical candidate; dose escalation trial reported.
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Filed a final prospectus for a securities offering. SEC Form 424B4. Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 5.03,9.01). Source
Filed a final prospectus for a securities offering. SEC Form 424B4. Source
Filed a final prospectus for a securities offering. SEC Form 424B4. Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a financing. SEC Form S-1. Source
Reported a reverse stock split. SEC Form 8-K (Items 5.03,9.01). Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 5.03,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio